DEGARELIX COMPARED TO LEUPROLIDE DEPOT 7.5 MG IN A 12- MONTH RANDOMISED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY IN PROSTATE CANCER PATIENTS

2008 ◽  
Vol 7 (3) ◽  
pp. 205 ◽  
Author(s):  
L. Boccon-Gibod ◽  
L. Klotz ◽  
H. Schröder ◽  
C. Andreou ◽  
B.E. Persson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Phase Iii ◽  
Open Label ◽  
Parallel Group ◽  
Phase Iii Study

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

2008 ◽  
Vol 102 (11) ◽  
pp. 1531-1538 ◽  
Author(s):  
Laurence Klotz ◽  
Laurent Boccon-Gibod ◽  
Neal D. Shore ◽  
Cal Andreou ◽  
Bo-Eric Persson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Open Label ◽  
Parallel Group ◽  
Phase Iii Study

scholarly journals Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer

2010 ◽  
Vol 184 (6) ◽  
pp. 2313-2319 ◽  
Author(s):  
Matthew R. Smith ◽  
Laurence Klotz ◽  
Bo-Eric Persson ◽  
Tine Kold Olesen ◽  
Arthur A.M. Wilde
Keyword(s):  
Prostate Cancer ◽  
Phase Iii ◽  
Cardiovascular Safety ◽  
Open Label ◽  
Phase Iii Trial ◽  
Parallel Group
Sign in / Sign up

Export Citation Format

Share Document